Shares of Sarepta Therapeutics (SRPT +4.1%) pop after Glaxo SmithKline (GSK +0.1%) says that...

Shares of Sarepta Therapeutics (SRPT +4.1%) pop after Glaxo SmithKline (GSK +0.1%) says that Duchenne muscular dystrophy patients treated with its experimental drug drisapersen have been hospitalized due to kidney toxicity and low platelet counts. SRPT is meeting with FDA officials this month to discuss the possibility of an accelerated approval filing for its DMD drug eteplirsen based on a completed phase II study. Eteplirsen's adverse event reports have been relatively unblemished to date.